Biogen was founded in 1978 in Geneva, Switzerland (and soon moved to Cambridge, Massachusetts) by a group of legendary, Nobel Prize-winning biologists, including Walter Gilbert and Phillip Sharp. Alongside Genentech and Amgen Biogen was one of the definitive foundational pioneers of the modern biotechnology industry. They proved that recombinant DNA technology could be utilized to manufacture complex proteins to treat severe human diseases, moving the industry away from traditional chemical synthesis into the complex world of biologics.
The Multiple Sclerosis (MS) Franchise
The defining, multi-decade financial engine for Biogen was its clear dominance in the treatment of Multiple Sclerosis (MS). In 1996, the company launched Avonex, an effective biologic drug that essentially established the market. They followed this success in 2013 with Tecfidera, a lucrative oral MS drug. Because these drugs treated a severe, debilitating chronic disease, they commanded, astronomical price premiums. This concentrated MS franchise provided Biogen with incredible, predictable cash flow, transforming the company into a multi-billion-dollar biotech titan.
The Patent Cliff and The Strategic Pivot
In the late 2010s, Biogen faced a, existential crisis. The patents for its foundational MS drugs (specifically Tecfidera) were challenged and eventually defeated in court. The market was instantly flooded with cheap generic alternatives, and Biogen's extensive, reliable cash flow began to violently collapse. To survive, the company had to execute a strategic pivot. They chose to attack arguably the most difficult, catastrophic challenge in modern medicine: Alzheimer's disease. The scientific "graveyard" of failed Alzheimer's drugs was, having destroyed billions of dollars of R&D capital from other pharmaceutical titans.
The Aduhelm Controversy (The Alzheimer's Gamble)
In 2021, Biogen achieved what appeared to be a substantial, historic victory: the FDA approved Aduhelm, the first new Alzheimer's drug in two decades. However, the approval instantly sparked arguably the most major, explosive controversy in modern FDA history. The scientific data was ambiguous; many scientists argued the drug didn't actually improve cognitive function, despite reducing amyloid plaque in the brain. Biogen launched the drug with a staggeringly high price tag ($56,000 a year). The backlash was true. Medicare largely refused to cover the drug, doctors refused to prescribe it, and the commercial launch was a catastrophic, humiliating failure, devastating Biogen's stock price.
The Leqembi Redemption and the Turnaround
Desperate to recover from the Aduhelm disaster, Biogen (partnered with the Japanese pharmaceutical company Eisai) pushed forward with a second Alzheimer's drug, Leqembi. In 2023, Leqembi received full FDA approval, possessing significantly stronger, credible clinical data proving that it actually slowed cognitive decline. Today, under the leadership of a new CEO (Christopher Viehbacher) Biogen is executing a corporate turnaround. The company is cutting costs, laying off thousands of employees, and desperately attempting to execute a flawless commercial launch for Leqembi, betting that this single drug can replace the lost MS revenue and ensure the survival of the legendary biotech pioneer.
